Xeris Biopharma Holdings, Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +7.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.02 | $0.00 | -100.0% | Miss | Q2 FY26 call |
| Q1 FY26 | $0.00 | $0.01 | not reported | Beat | |
| Q4 FY25 | $0.03 | $0.06 | +100.0% | Beat | |
| Q3 FY25 | $0.01 | $0.00 | -100.0% | Miss | |
| Q2 FY25 | not reported | $-0.01 | not reported | not reported | |
| Q1 FY25 | $-0.07 | $-0.06 | +14.3% | Beat | Q1 FY25 call |
| Q4 FY24 | $-0.07 | $-0.03 | +57.1% | Beat | |
| Q3 FY24 | $-0.09 | $-0.06 | +33.3% | Beat | |
| Q2 FY24 | $-0.11 | $-0.10 | +9.1% | Beat | |
| Q1 FY24 | $-0.12 | $-0.14 | -16.7% | Miss | |
| Q4 FY23 | $-0.09 | $-0.10 | -11.1% | Miss | |
| Q3 FY23 | $-0.12 | $-0.09 | +25.0% | Beat |
Back to XERS overview · XERS holders · XERS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.